Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation During Treatment With Three Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol (EE) and 2.10 mg Gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2014
At a glance
- Drugs Ethinylestradiol/gestodene (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 19 Apr 2012 Bayer HealthCare trial company and lead trial centre added as reported by European Clinical Trials Database record.
- 17 Jan 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 09 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.